Biotech Adam Feuerstein On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price
Biotech Rebecca Robbins After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors
Biotech Adam Feuerstein, Matthew Herper and Damian Garde At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech
Biotech Matthew Herper A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
Biotech Matthew Herper, Damian Garde, Rebecca Robbins and Adam Feuerstein The ghosts of JPMs past: How 20 years of deals, scandal, and science have shaped health care
Biotech Adam Feuerstein Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?
Health Tech Rebecca Robbins Eyeing more data, Livongo will integrate continuous glucose monitor into diabetes coaching program